Xcorporeal to Present at Needham Biotechnology & Medical Technology Conference on Thursday, June 12th
June 09 2008 - 7:30AM
Business Wire
Xcorporeal, Inc. (AMEX:XCR) announced today that Dan Goldberger,
Chief Executive Officer at Xcorporeal, will be presenting at the
Seventh Annual Needham�Biotechnology & Medical
Technology�Conference, at the New York Palace Hotel in New York
City, on Thursday, June 12, 2008 at 3:30 p.m. Eastern Time. The
Company�s presentation will also be webcast live and archived for
future reference, for 30 days, at
www.wsw.com/webcast/needham25/xcor/ and also available on the
Company�s website at www.xcorporeal.com. About Xcorporeal
Xcorporeal, Inc. is a medical device company developing an
innovative extra-corporeal platform technology to be used in
devices to replace the function of various human organs. These
devices will seek to provide patients with improved, efficient and
cost effective therapy. The platform leads to three initial
products: a Portable Artificial Kidney (PAK) for hospital Renal
Replacement Therapy, a PAK for home hemodialysis, and a Wearable
Artificial Kidney (WAK) for continuous ambulatory hemodialysis. For
the hospital market, Xcorporeal is developing a portable,
multifunctional renal replacement device that will offer
cost-effective therapy for those patients suffering from Acute
Renal Failure, which causes a rapid decline in kidney function. In
the U.S., the disease affects more than 200,000 patients annually
with a mortality rate approaching 50%, according to a study
published in the Clinical Journal of American Society of Nephrology
in 2006. The Xcorporeal platform technology is designed to provide
cost-effective, continuous therapy. The Company has completed its
functional prototype of the product, which is currently undergoing
bench testing, and anticipates submitting a 510(k) filing with the
Food and Drug Administration (FDA) during the fourth quarter of
2008. The Company also plans to commercialize a home hemodialysis
device for the chronic End Stage Renal Disease (ESRD) market,
comprised of patients in whom the kidneys have ceased to function.
The Company�s devices are intended to combine the best attributes
of currently marketed home hemodialysis machines to offer patients
convenient, durable and truly portable treatments at home. The
Company believes its devices will provide a cost-effective
alternative to current home treatment modalities, due to their
ability to offer hemodialysis without the need for large quantities
of dialysate fluid or purified water. The Company has also
completed its functional prototype of the product, which is
currently undergoing bench testing, and anticipates submitting a
510(k) with the FDA during the second half of 2009. The Company�s
WAK is also a device for the chronic treatment of ESRD. The Company
has successfully demonstrated a prototype system that weighs less
than 6 kg., is battery operated, and can be worn by an ambulatory
patient. This miniature, wearable device is intended to enable
continuous (up to 24 hours � 7 days per week) renal replacement
therapy at home. Increasing dialysis time has previously been shown
to reduce morbidity and improve quality of life of ESRD patients.
The WAK has recently been featured in articles written by the Los
Angeles Times, The Lancet, Kidney International, and various other
medical periodicals. Additional Company information may be found on
the Internet at: www.xcorporeal.com. Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond the company's control that may cause actual
results to differ materially from stated expectations. These risk
factors include, among others, limited operating history,
difficulty in developing, exploiting and protecting proprietary
technologies, intense competition and substantial regulation in the
medical device industry; and additional risks factors as discussed
in the reports filed by the Company with the Securities and
Exchange Commission, which are available on its website at
http://www.sec.gov.
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Oct 2023 to Oct 2024